Core Viewpoint - The pricing power battle in the medical aesthetics industry is intensifying, with New Oxygen (SY.O) challenging upstream manufacturers over the pricing of its "youthful needle" products, leading to significant price reductions and disputes regarding product sourcing and compliance [1][2][3]. Group 1: Pricing Strategy and Market Dynamics - New Oxygen launched its "Miracle Youth 1.0" at a price of 4,999 yuan per unit, marking the first time the market price for youthful needles reached the 5,000 yuan range, while the manufacturer's price was 16,800 yuan per unit [1]. - In June, New Oxygen introduced "Miracle Youth 2.0" at 5,999 yuan per unit, using a product from Saint Boma, which has a market average price of approximately 18,800 yuan per unit [1]. - On December 15, New Oxygen's youth clinics offered a group purchase price as low as 949 yuan per unit, representing a drastic reduction of about 95% compared to the manufacturer's controlled price of 16,800-18,800 yuan per unit [2]. Group 2: Manufacturer Responses and Industry Implications - Multiple upstream manufacturers have publicly distanced themselves from New Oxygen, with Fiman Bio announcing it ceased supplying products to New Oxygen and its clinics, warning that continued sales could indicate non-compliance or counterfeit products [2]. - New Oxygen argues that the ongoing pricing battle reflects a structural shift in the medical aesthetics market from a "seller's market" to a "buyer's market," driven by the approval of more products like youthful needles and hyaluronic acid [2]. - The company believes that a rational price return will benefit both upstream and downstream players, allowing for stable orders that can reduce production and R&D costs, while also fostering healthier customer acquisition and repurchase models [3].